Fig. 3: Osimertinib duration of treatment by candidate mechanism and T790M status. | Nature Communications

Fig. 3: Osimertinib duration of treatment by candidate mechanism and T790M status.

From: Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Fig. 3: Osimertinib duration of treatment by candidate mechanism and T790M status.

Swimmer plot indicating the duration of treatment with osimertinib (months) by candidate mechanism and T790M status (n = 78). Source data are provided in the Supplementary Data 1 file. X time of death for patients who have died, O date last known alive for patients who have not died, D time of study discontinuation.

Back to article page